Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B known ✓ | Q13224 | 12/20 | 0.72 |
| ▸ | GRIN1 known ✓ | Q05586 | 10/20 | 0.72 |
| ▸ | GRIN2D known ✓ | O15399 | 6/20 | 0.72 |
| ▸ | GRIN3B known ✓ | O60391 | 6/20 | 0.72 |
| ▸ | GRIN2A known ✓ | Q12879 | 6/20 | 0.72 |
| ▸ | GRIN2C known ✓ | Q14957 | 6/20 | 0.72 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 6/20 | 0.72 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.59 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.59 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.59 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.57 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.57 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.57 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.57 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.57 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.57 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45769 | 0.98 | GRIN2B (0.68) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL7206541 | 0.95 | GRIN2B (0.65) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| Sulfuric Acid SCHEMBL4014387 | 0.87 | LMNA (0.65) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL1737052 | 0.85 | GRIN1 (0.62) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| Hydrochloric Acid SCHEMBL4003818 | 0.82 | NOS2 (0.64) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| Hydrochloric Acid SCHEMBL4737504 | 0.82 | NOS2 (0.92) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| Amphetamine SCHEMBL28092355 | 0.81 | TAAR1 (0.66) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL10425011 | 0.80 | GRIN2B (0.52) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL1736065 | 0.80 | TAAR1 (0.67) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A | |
| Hydrochloric Acid SCHEMBL4737688 | 0.80 | GRIN2B (0.63) | GRIN2BGRIN1GRIN2DGRIN3BGRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025037034-A1 | THIENOTHIADIAZINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2025-02-20 | — | — | WO | disclosed |
| WO-2020218835-A1 | NOVEL POLYIMIDE-TYPE POLYMER AND PREPARATION METHOD THEREFOR | 서울대학교 산학협력단 | 2020-10-29 | — | — | WO | disclosed |
| EP-2773624-A1 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS | Boehringer Ingelheim International GmbH (DE) | 2014-09-10 | — | — | EP | disclosed |
| CN-104024231-A | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS | BOEHRINGER INGELHEIM INT | 2014-09-03 | — | — | CN | disclosed |
| US-8791260-B2 | Process for the preparation of acylguanidines and acylthioureas | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20140039189-A1 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| WO-2013064451-A1 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109856-A1 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1032556-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | WYETH CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1032556-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1032556-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-09-06 | — | — | EP | disclosed |
| US-5945455-A | Amine and amidine containing compounds as weight reducing agents | UNIVERSITY OF STRATHCLYDE (GB) | 1999-08-31 | — | — | US | disclosed |
| WO-1999020599-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0825855-A1 | AGENTS FOR REDUCING WEIGHT | University of Strathclyde (GB) | 1998-03-04 | — | — | EP | disclosed |
| US-5602277-A | Substituted benzene derivatives useful as neuraminidase inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-02-11 | — | — | US | disclosed |
| WO-1996036325-A1 | AGENTS FOR REDUCING WEIGHT | UNIVERSITY OF STRATHCLYDE (GB) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039189-A1 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS | SCNN1B, SCNN1A, SCNN1G | GRIN2B 806/4885GRIN1 801/4885GRIN2D 1705/4885 |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | GRIN2B 383/4885GRIN1 496/4885GRIN2D 684/4885 |
| US-20130109856-A1 | NOVEL PROCESS FOR THE PREPARATION OF ACYLGUANIDINES AND ACYLTHIOUREAS | SCNN1B, SCNN1A, SCNN1G | GRIN2B 806/4885GRIN1 801/4885GRIN2D 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.